A common glycan structure on immunoglobulin G for enhancement of effector functions
Antibodies have been developed as therapeutic agents for the treatment of cancer, infection, and inflammation. In addition to binding activity toward the target, antibodies also exhibit effector-mediated activities through the interaction of the Fc glycan and the Fc receptors on immune cells. To identify the optimal glycan structures for individual antibodies with desired activity, we have developed an effective method to modify the Fc-glycan structures to a homogeneous glycoform. In this study, it was found that the biantennary N-glycan structure with two terminal alpha-2,6-linked sialic acids is a common and optimized structure for the enhancement of antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and antiinflammatory activities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
Proceedings of the National Academy of Sciences of the United States of America - 112(2015), 34 vom: 25. Aug., Seite 10611-6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lin, Chin-Wei [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.12.2015 Date Revised 13.11.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1073/pnas.1513456112 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM251643522 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM251643522 | ||
| 003 | DE-627 | ||
| 005 | 20231224162436.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1073/pnas.1513456112 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0838.xml |
| 035 | |a (DE-627)NLM251643522 | ||
| 035 | |a (NLM)26253764 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lin, Chin-Wei |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A common glycan structure on immunoglobulin G for enhancement of effector functions |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.12.2015 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Antibodies have been developed as therapeutic agents for the treatment of cancer, infection, and inflammation. In addition to binding activity toward the target, antibodies also exhibit effector-mediated activities through the interaction of the Fc glycan and the Fc receptors on immune cells. To identify the optimal glycan structures for individual antibodies with desired activity, we have developed an effective method to modify the Fc-glycan structures to a homogeneous glycoform. In this study, it was found that the biantennary N-glycan structure with two terminal alpha-2,6-linked sialic acids is a common and optimized structure for the enhancement of antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and antiinflammatory activities | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Fc glycosylation | |
| 650 | 4 | |a endoglycosidase | |
| 650 | 4 | |a glycoengineered antibodies | |
| 650 | 4 | |a homogeneous antibodies | |
| 650 | 4 | |a sugar oxazoline | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Bacterial Proteins |2 NLM | |
| 650 | 7 | |a FCGR3A protein, human |2 NLM | |
| 650 | 7 | |a Immunoglobulin Fc Fragments |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Polysaccharides |2 NLM | |
| 650 | 7 | |a Receptors, IgG |2 NLM | |
| 650 | 7 | |a Sialic Acids |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a endo-N-acetylneuraminidase |2 NLM | |
| 650 | 7 | |a EC 3.2.1.- |2 NLM | |
| 650 | 7 | |a Neuraminidase |2 NLM | |
| 650 | 7 | |a EC 3.2.1.18 |2 NLM | |
| 650 | 7 | |a alpha-L-Fucosidase |2 NLM | |
| 650 | 7 | |a EC 3.2.1.51 |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 650 | 7 | |a Acetylglucosamine |2 NLM | |
| 650 | 7 | |a V956696549 |2 NLM | |
| 700 | 1 | |a Tsai, Ming-Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Shiou-Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Tsung-I |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Kuo-Ching |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ying-Chih |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Meng-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Chia-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Tseng, Yung-Chieh |e verfasserin |4 aut | |
| 700 | 1 | |a Shivatare, Sachin S |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chia-Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Chao, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Shi-Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Shih, Hao-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Yi-Fang |e verfasserin |4 aut | |
| 700 | 1 | |a You, Tsai-Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Jung-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Yu-Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yih-Shyan |e verfasserin |4 aut | |
| 700 | 1 | |a Chuang, Hong-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Chia-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Charng-Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Chiu-Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Nan-Horng |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Che |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Chung-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Chi-Huey |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Proceedings of the National Academy of Sciences of the United States of America |d 1915 |g 112(2015), 34 vom: 25. Aug., Seite 10611-6 |w (DE-627)NLM000008982 |x 1091-6490 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2015 |g number:34 |g day:25 |g month:08 |g pages:10611-6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1073/pnas.1513456112 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2015 |e 34 |b 25 |c 08 |h 10611-6 | ||